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Multivariate assays using gene expression as their contributing factors, such as
the centroid-based PAM50 Breast Cancer Intrinsic Classifier, are becoming commonly
used in assisting treatment decisions in medicine, especially in oncology. Although
physicians may rely on these multivariate assays for planning treatment, little is
known about the effects on the results of an assay due to the intrinsic error in the
laboratory process and measuring its contributing factors. While we expect that clas-
sification of samples in proximity to one of the centroids defining the tumor classes will
be stable with respect to experimental errors in the gene expression measurements,
what happens to the samples not in proximity to a single centroid is unknown.
Results reported to the attending physician may be misleading because he or she
is receiving no information about the probability for sample misclassification. Given
the serious consequences due to ambiguous results in clinical classifications, methods
to measure the effects of a multivariate assay’s intrinsic errors need to be established
and communicated to attending physicians. In this study, a method to characterize
the technical uncertainty in the classification of centroid-based multivariate assays, is
developed and described, using the PAM50 Breast Cancer Intrinsic Classifier as the
model multivariate assay. Furthermore, the described method provides a general and
individual classification confidence measurement that advances multivariate assays
towards personalized healthcare by providing personalized confidence measurements
on the assay’s result. Finally, this study explores whether using parametric versus
nonparametric distance measurements is most effective when using a single gene
expression platform, such as microarray or Real-time, quantitative Polymerase Chain
Reaction.
To my wife, Cheri Michelle, and my children and parents for their incredible
support.
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Breast cancer has captured the attention of medical professionals, researchers,
women, and their loved ones around the world because the disease’s cure has been
elusive, due to its complexity. Breast cancer’s complexity largely stems from its
heterogeneity on the levels of molecular alterations, cellular composition, and clinical
outcome – making proper diagnosis and treatment difficult [1]. Breast cancer is
the most common cancer in women, amounting to nearly 1 in 3 cancer diagnoses,
and is the second leading cause of cancer deaths among women, according to the
American Cancer Society [2]. Furthermore, more than 230,000 new cases of invasive
breast cancer as well as more than 57,000 in situ cases were expected to be diagnosed
during 2011. Approximately 40,000 breast cancer deaths were also expected during
2011 [2]. Clearly, breast cancer dramatically changes the lives of millions of individuals
annually, in the United States alone, when also considering the friends and loved ones
for each newfound patient. However, researchers and physicians are making progress
in efforts to eradicate breast cancer. For example, the breast cancer mortality rate
decreased by approximately 24% to 37% between 1990 and 2007, which was attributed
to early detection by screening and adjuvant treatment [2,3]. Such a dramatic decrease
in breast cancer mortality is encouraging, but certainly not sufficient. Further efforts
to understand the biological nature of breast cancer will ameliorate treatment for all
cancers at any stage.
In an effort to better understand the biological nature of breast cancer, researchers
and physicians have worked together to develop several multivariate assays (MVA)
designed to elucidate the biological nature of breast tumors. MVAs are assays that
exploit multiple biological measurements, referred to as contributing factors, to as-
certain a clinical result. Example MVAs include the PAM50 Breast Cancer Intrinsic
2Classifier, Oncotype DX R©, BreastOncPx
TM
, and MammaPrint R© – each of which
are both prognostic and predictive of a tumor’s drug and chemotherapy sensitivity
[1, 4–13]. Although these MVAs have proven useful, little is known about the effects
of intrinsic technical uncertainty on the MVA’s results. Each of the aforementioned
MVAs measure expression of several genes, ranging from 14 to 70, making them
highly complex. In fact, each gene measured in the MVA, although necessary to
understand the biological nature of the tumor, is a separate dimension that introduces
its own natural variation, or error, which may make results more unpredictable. As
MVAs become more commonplace in medicine, a method to characterize the intrinsic
technical uncertainty of such complex tests generally, as well as how to measure the
confidence of individual results, will be essential.
Technical uncertainty may be separated into intrinsic error from measuring de-
vices and in vitro biological processes, as well as intrinsic and explicit classification
uncertainties, among others. There are also extrinsic factors such as local climate
and human interactions that will affect MVAs. Essentially, technical uncertainty
involves most aspects from the time a sample is received by the reference laboratory
until a clinical report is generated. To be widely applicable, a method capable of
characterizing intrinsic technical uncertainty must be scalable and generalizable. By
developing a scalable and generalizable method to characterize intrinsic technical
uncertainty, researchers will be able to assess and validate the technical aspect of
current and future MVAs, as well as minimize the effects of technical uncertainty on
the MVA’s final result – making patient diagnosis and treatment more accurate and
predictable.
1.2 Main Objectives
Several MVAs are already used in medicine and, in general, MVAs are likely be-
come a standard of care for many complex diseases; however, three main shortcomings
regarding MVAs to address, which are the primary objectives of this research, are as
follows:
1. There is currently no standard method to characterize the intrinsic technical
uncertainty of MVAs
32. There is currently no method to measure the confidence of individual results
3. Little is known regarding the effectiveness of using a parametric measurement
within a single platform (e.g., microarray or RT-qPCR) versus using a nonpara-
metric measurement.
A standard method to assess and validate the technical aspect of MVAs is essential
because it will allow researchers to characterize and minimize the effects of intrinsic
technical uncertainty (error) on an MVA’s final result. Little is known about the
effects of intrinsic technical error in measuring an MVA’s contributing factors on
the MVA’s results. Likewise, little is known about how to measure the effects.
Given the complexity of MVAs, results may be unpredictable, or easily corrupted
by minor changes or mistakes in the process. For example, if a mistake is made
in the process that causes a single contributing factor to be mismeasured, there is
currently no method to assess the potential ramifications. Furthermore, there is no
method to assess how much variation, or error, can exist within the process without
compromising the results. Developing a generalizable method to characterize the
intrinsic technical uncertainty is the first objective of this research.
A method to measure the confidence of individual results will advance MVAs
toward personalized healthcare by providing personalized confidence measurements
on the MVA’s result. Clinical assays routinely report a general summary statistic
measuring how well the assay performed on an independent test set when compared
to the results of a reference standard method; however, such summary statistics do
not provide personalized information on the confidence that the result for a specific
sample was accurate. Since summary statistics, by nature, are meant to represent
an entire distribution of results, a physician has no choice but to assume that all
results provided by an MVA have equal confidence to the confidence portrayed in the
summary statistic. There will undoubtedly be samples whose confidence is poor, but
the physician will be uninformed that he or she should give special attention to the
situation. Developing a method to measure the confidence of individual results is the
second objective of this research.
4An essential aspect of developing and assessing centroid-based MVAs (cbMVA),
specifically, is identifying the best distance metric to determine classifications, how-
ever, little is known regarding when to use parametric versus nonparametric mea-
surements. Given the limitless variations possible when designing cbMVAs, defining
whether a parametric or nonparametric measurement is most appropriate is difficult
at best. Nevertheless, a specific situation of interest is which measurement type is
most appropriate when using a single gene-expression platform such as microarray or
Real-time, quantitative PCR (RT-qPCR). The PAM50 clinical assay uses RT-qPCR
exclusively and will be used to explore the potential ramifications. Since there
are several possible measurements within both the parametric and nonparametric
categories, two specific measurements of interest will be considered: euclidean, which
is parametric, and Spearman’s Rho (ρ), which is nonparametric. Exploring the effects
of using euclidean versus ρ as a distance metric when using RT-qPCR exclusively is
the third and final objective of this research.
CHAPTER 2
BACKGROUND
2.1 Uncertainty in Centroid-based
Multivariate Assays
MVAs using gene expression as their contributing factors are becoming common-
place in assisting treatment decisions in medicine, especially in oncology. Examples
of MVAs available for planning breast cancer treatment include the 55-gene subtype
classifier (PAM50 Breast Cancer Intrinsic Classifier) [1], the 21-gene prognosis assay
(Oncotype DX R©) [14], the 14-gene prognosis assay (BreastOncPx
TM
) [15] and the
70-gene prognosis assay (MammaPrint R©) [16]. Although physicians may rely on
these MVAs for planning treatment, little is known about the effects of intrinsic
technical error in measuring an MVA’s contributing factors on the MVA’s results – in
this case, all laboratory steps required for preparing a sample (post RNA extraction),
preparing the assay, and the instrumental errors for measuring gene expression. While
we expect that classification of samples in proximity to one of the centroids defining
the tumor classes, referred to as archetypal samples here, will be stable with respect to
experimental errors in the gene expression measurements, it is unknown what happens
to the samples not in proximity to a single centroid. For example, if a sample lies
in a “gray” area where the intrinsic errors in the gene expression measurements may
result in a change of its classification each time the sample is run, the results reported
to the attending physician may be misleading because he or she is getting the results
from only one measurement and no information about the probability for sample
misclassification. Given the serious consequences due to ambiguous results in clinical
classifications, methods to measure the effects of an MVA’s intrinsic errors need to
be established and communicated to attending physicians.
The complexity of MVAs demonstrates the challenge of identifying and under-
standing error sources from the moment a sample is received by the reference labora-
6tory until a clinical report is generated. In short, each contributing factor measured
within an MVA is a new dimension with its own associated measurement error.
Further error sources to be considered include heterogeneity (e.g., heterogeneity due
to molecular and cellular composition) and sample preparation, as well as technical
variability, which may be separated into error from measuring devices and in vitro bio-
logical processes, as well as intrinsic and explicit classification uncertainties. Potential
classification uncertainties include differing metrics to define class boundaries, such
as euclidean distance versus Spearman’s Rho (ρ), as well as differing algorithms to
determine the classification. The focus of this research was to characterize technical
uncertainty within MVAs, in general, and more specifically how to estimate and
measure the effect that intrinsic gene expression measurement errors, including those
associated with sample and assay preparation, have on final MVA results overall (i.e.,
across large data sets), as well as for individual samples.
2.2 PAM50 Breast Cancer
Intrinsic Classifier
In 2009 Parker et al. proposed a 50-gene expression signature, named the PAM50,
as a method to standardize breast cancer subtype classification through gene expres-
sion profiling – in contrast to the conventional immunohistochemistry (IHC) and
fluorescence in situ hybridization (FISH) methods. Both IHC and FISH have been
criticized as being subjective or insufficient, or both, due to differing techniques, visual
interpretation, and other inconsistencies [1, 17–24]. Conversely, quantitative values
allow for more objective analysis, such as those produced through gene expression
profiling techniques like microarray and RT-qPCR [1]. As such, the PAM50 is well
positioned to provide objective, reproducible subtype classification for breast cancer,
which is commonly classified into one of four recognized biological subtypes known
as Luminal A, Luminal B, HER2-enriched, and Basal-like [1, 25–28].
The PAM50, later released as a clinical assay in 2011 at ARUP Laboratories as the
PAM50 Breast Cancer Intrinsic Classifier (PAM50 assay), is a complex MVA based
on gene expression for several genes. PAM50 measures the expression level of 55 genes
(50 classifier genes and 5 housekeepers) creating a “signature” that is compared, using
Spearman’s Rho (ρ) as a distance metric, to each of five centroids [1,29] representing
7the Luminal A, Luminal B, HER2-enriched and Basal-like subtypes [1,26,27], as well
as Normal-like tissue. The tumor sample is then classified as the subtype to which it
is most similar by ρ.
Although the PAM50 is young, numerous studies have already shown the PAM50
subtype classification is both prognostic as well as predictive of a tumor’s drug and
chemotherapy sensitivity [1, 4–6]. Moreover, a recent study has also shown that the
PAM50 may better identify low-risk ER+ tumors, when compared to Oncotype DX R©,
demonstrating PAM50’s potential value in breast cancer treatment [30].
Despite all of the benefits the PAM50 and other prognostic MVAs provide, little
is known about how to assess the overall and individual reproducibility of an MVA’s
final result, given the intrinsic technical uncertainty within the MVA system (e.g., in-
strument measurement variability, RT-qPCR variability, etc.). As such, it is essential
to develop a method to characterize the uncertainty within a complex MVA and its
effects on the MVA’s final result.
2.3 Distance Metrics – Spearman’s
Rho (ρ) vs. Euclidean
Distance metrics are a key element of interest in the characterization of error
within cbMVAs, specifically. Numerous distance metrics could be used and were ex-
plored during development of the PAM50; however, Spearman’s Rho (ρ) was identified
as the ideal distance metric to maintain consistency across gene expression platforms
(e.g., RT-qPCR and microarray) [1]. Spearman’s nonparametric approach involving a
value’s rank, when compared to its sister values, rather than the raw value itself makes
the metric more robust across platforms because nonparametric statistics are more
capable of assessing data that do not belong to any particular distribution (or different
distributions) [31]. However, nonparametric statistics have several disadvantages such
as being less specific (i.e., more generalized) because information is lost by using ranks
instead of raw values, and nonparametric tests have less power to reject a false null
hypothesis [31, 32]. Given clinical MVAs are likely to use a single platform (e.g.,
RT-qPCR), the benefits of a nonparametric test like Spearman’s Rho (ρ) come into
question. Parametric measurements, on the other hand, such as Euclidean distance,
although not ideal across platforms, may be more accurate and consistent within a
8single platform, and thus be a better choice for the clinical assays like the clinical
PAM50 assay.
2.4 General and Individual
Classification Confidence
Perhaps the most important element of characterizing intrinsic technical uncer-
tainty in the classification of MVAs is to measure uncertainty’s effect on the MVA’s
final results – in other words, measuring the overall confidence of the MVA’s final
results. However, this research also seeks to take an MVA’s accountability one step
further and provide a confidence measurement on the results of individual patient
samples, based on the premise that knowing the overall reproducibility of an MVA
provides little information for the confidence of a given sample’s result. Essentially,
the overall confidence of any assay is an average confidence, which suggests there is
an unknown distribution of confidence values for individual samples. For example,
clinical assays commonly report sensitivity and specificity of the assay, which repre-
sents the assay’s overall ability to distinguish between classes; however, sensitivity
and specificity are merely an overall measurement of confidence from a test set where
truth is “known” (assumed) based on some reference standard. Such information
provides little information for a sample lacking knowledge of the reference standard,
except to say the assay “overall” provides sensitivity x and specificity y. A more
specific measurement is essential to providing personalized confidence measurements.
The PAM50 uses Spearman’s Rho (ρ) as a distance metric to determine the sub-
type of a tumor. Several statistical tests exist for determining statistical significance
of ρ [33–35], but each test is insufficient for one of two reasons: (1) the test is not
specific for individual samples; and (2) the test does not relate multiple ρ values.
Statistical tests, such as those in the first case, are generally tailored for sample means
rather than individual measurements and are not suited for calculating a statistical
measurement for an individual breast tumor sample classification. Regarding the
second case, Spearman’s Rho (ρ) is capable of determining whether any two variables
(e.g., tumors) are significantly correlated by ρ by testing whether ρ is significantly
different from 0; however, this test is incapable of relating multiple ρ values. In other
words, when the tumor is compared to each of the five centroids, the tumor may
9be significantly correlated to more than one centroid, especially since the expression
profiles for all centroids and the test sample are based on breast tissue. In fact,
preliminary analyses suggest that > 99% of all test samples are significantly correlated
with more than one centroid, and > 85% are significantly correlated to all five.
Currently, there is no way to determine whether one classification is statistically the
“best” classification. A new method to measure confidence of individual samples is
clearly needed, and if medicine is, indeed, to become personalized, then clinical assays
must provide personalized results, including personalized confidence measurements.
2.5 The Monte Carlo Method
A method that is capable of characterizing the technical uncertainty of MVAs
must be thorough, scalable, and generalizable because of the complexity of MVAs – an
ideal situation to employ the Monte Carlo method [36–39]. The Monte Carlo method
was developed by Stanislaw (Stan) Ulam, John von Neumann, Nicholas Metropolis,
and others at the Los Alamos Laboratory in the 1940’s while trying to characterize
neutron diffusion in fissionable materials, which is a complex, multidimensional prob-
lem [36–39] similar to characterizing technical uncertainty in MVAs. The Monte Carlo
method is particularly amenable to complex, multidimensional problems because it
uses random sampling from predefined statistical distributions for each dimension
(contributing factor) to perform what have become known as “mathematical ex-
periments” [38]. Furthermore, the upper limits on performing the “mathematical
experiments” are determined only by available time and computational resources –
both of which are readily available to researchers today. Allowing each contributing
factor to be randomly sampled from its own distribution makes the Monte Carlo
method highly scalable and generalizable, while being able to perform a large number
of “mathematical experiments” allows the method to be highly thorough.
Ulam’s Monte Carlo method has been used to solve numerous problems empiri-
cally. Ulam first conceived the idea in 1946 while playing the card game Solitaire, as
he later stated in 1983:
The first thoughts and attempts I made to practice [the Monte Carlo
method] were suggested by a question which occurred to me in 1946
as I was convalescing from an illness and playing solitaires [sic]. The
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question was what are the chances that a Canfield solitaire laid out with
52 cards will come out successfully? After spending a lot of time trying
to estimate them by pure combinatorial calculations, I wondered whether
a more practical method than “abstract thinking” might not be to lay it
out say one hundred times and simply observe and count the number of
successful plays. This was already possible to envisage with the beginning
of the new era of fast computers, and I immediately thought of problems
of neutron diffusion and other questions of mathematical physics, and
more generally how to change processes described by certain differential
equations into an equivalent form interpretable as a succession of random
operations. Later... [in 1946, I ] described the idea to John von Neumann
and we began to plan actual calculations [37].
As Ulam stated, he immediately applied the idea to understanding neutron diffusion,
and more generally how to apply the method to problems pertaining to differential
equations. In fact, the Monte Carlo method has since been shown to be useful in
problems where conventional analytics are not feasible [38,40,41]. After some lengthy
preparation, Ulam et al. later computed nine problems specific to material configu-
rations, neutron distributions, and running times [38]. The Monte Carlo method has
since been used to solve problems in fluids, thermodynamics, neuroscience, and other




A comprehensive experimental study to estimate the effect that the intrinsic gene
expression measurement errors have on the classification of tumors and gene-score
classifications requires, in principle, repeated testing of a significant number of sam-
ples from each subtype and thorough analysis of the misclassifications observed. Such
a comprehensive approach is unfeasible in terms of cost and sample availability. Here
we have adopted a hybrid approach in which we perform repeated experimental
measurements on one sample from each subtype (i.e., Luminal A, Luminal B, HER2-
enriched and Basal-like) to determine the experimental variability of the measured
gene expression for each of the 50 genes included in the PAM50 assay. Using this
experimental information we proceed to generate a Gaussian error distribution that
can be used to generate multiple data sets by way of Monte Carlo simulations. These
simulations impose random errors, given by the Gaussian distribution, on the set
of experimental measured samples. Monte Carlo simulations are well suited for this
hybrid analysis because there is extensive literature for using this approach to estimate
errors in high-dimensional problems, such as fluids and thermodynamics [38, 42, 43],
where conventional analytics are not feasible [38,40,41]. The simulated data sets are
then classified by the standard PAM50 algorithm, and the misclassifications encoun-
tered in the synthetic data sets are used as a proxy for the PAM50’s misclassification
rate based on the assay’s intrinsic error.
Specifically, in this study we followed five major steps: (1) collect and prepare four
archetypal samples representative of each cancer subtype; (2) characterize the intrinsic
error for each gene’s expression values in the assay by making 12 measurements for
each gene’s expression on each archetypal sample and determine the distribution
type that best models the experimental errors; (3) using Monte Carlo simulations
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generate a sufficient number of simulated test samples, based on a defined confidence
interval width, by imposing the errors generated using the distribution from (2) onto
the archetypal samples; (4) determine the effect of the variability imposed in the
simulated samples on their classification; and (5) repeat steps (3) and (4) on an
independent set of samples from the GEICAM 9906 clinical trial (GEICAM) [46].
3.1 Archetypal Sample Collection
and Preparation
In order to characterize the error in gene expression measurements, four archetypal
samples representative of each cancer subtype with sufficient genetic material were
constructed – since most single samples do not have enough genetic material to be
tested more than twice. Cell lines representative of Basal-like (ME16C) and Luminal
B (MCF7) subtypes were grown in the Reagent Lab at ARUP Laboratories. Luminal
A and HER2-enriched subtypes were not readily available as a cell lines. As such, 20
patient tumor samples previously identified as archetypal Luminal A (10 samples) and
HER2-enriched (10 samples), based on PAM50 gene scores and classification, were
collected under IRB approved protocols at the University of Utah to be combined
and treated as single tumor samples.
RNA was extracted from tumor-enriched areas of formalin-fixed, paraffin-embed-
ded (FFPE) tissue blocks, containing more than 70% tumor cells, as determined
during review by a board-certified pathologist. Samples were deparaffinized us-
ing Citrus Clearing Solvent (Richard-Allen Scientific, Kalamazoo, MI, http://www.
thermofisher.com) followed by dehydration in absolute ethanol. RNA extraction
was completed on a Biomek NX Laboratory Automation Workstation (Beckman Coul-
ter, Beverly, MA, http://www.beckmancoulter.com) using the AgenCourt Forma-
Pure Kit (Beckman Coulter, Beverly, MA, http://www.beckmancoulter.com) ac-
cording to the manufacturer’s instructions and including a DNase I step. RNA
quantification was done on a Paradigm Detection Platform (Beckman Coulter, Bev-
erly, MA, http://www.beckmancoulter.com) using the Quant-iT RiboGreen As-
say Kit (Invitrogen, Carlsbad, CA, http://www.invitrogen.com). cDNA synthe-
sis was performed on the Biomek FX Laboratory Automation Workstation (Beck-
man Coulter, Beverly, MA, http://www.beckmancoulter.com) using 600 ng of RNA,
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uracil containing dNTPs (Invitrogen, Carlsbad, CA, http://www.invitrogen.com),
random primers (Invitrogen, Carlsbad, CA, http://www.invitrogen.com), gene-
specific, downstream PCR primers (Idaho Technology, Salt Lake City, UT, http://
www.idahotech.com), and SuperScript III Reverse Transcriptase (Invitrogen, Carls-
bad, CA, http://www.invitrogen.com).
Each 5 µL reaction contained 1X LightCycler 480 SYBR Green I Master Mix
(Roche Applied Sciences, Indianapolis, IN, http://www.roche-applied-science.
com) and 1.67 ng cDNA were added to the experimental sample wells. Sample cDNA
was incubated with LightCycler Uracil-DNA Glycosylase (Roche Applied Sciences,
Indianapolis, IN, http://www.roche-applied-science.com) at 40 ◦C for 10 min
and inactivated at 95 ◦C for 10 min prior to performing RT-qPCR. RT-qPCR was
performed on the LightCycler (LC) 480 (Roche Applied Sciences, Indianapolis, IN,
http://www.roche-applied-science.com) as follows: 45 cycles at 95 ◦C for 4 sec,
58 ◦C for 6 sec and 72 ◦C for 6 sec. To assure target specificity, RT-qPCR was followed
by a melting curve analysis: 95 ◦C for 15 sec, 65 ◦C for 1 min followed by raising the
temperature to 99 ◦C while taking 10 fluorescence acquisitions/◦C. We then classified
the RT-qPCR data from each run. One run from the Luminal A sample failed quality
control and was not included in further analysis.
3.2 Error Characterization
In order to estimate the intrinsic experimental error in gene expression measure-
ments within our laboratory, we performed 12 measurements for each gene within each
archetypal sample. Specifically, each of the four archetypal samples was separated
into, and treated as 12 individual samples (after extraction), and measured by RT-
qPCR on the Roche LightCycler (LC) 480 (Roche Applied Sciences, Indianapolis, IN,
http://www.roche-applied-science.com). The error distribution function type
could not be estimated using only the 12 measurements for each gene within a given
sample subtype, therefore to determine the error distribution function type for each
gene, all four sample subtypes were median-centered by gene and combined, giving
47 data points per gene, since one of the archetypal Luminal A samples failed quality
control. As depicted in Figure 3.1, the resultant error distributions for each gene
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can be reasonably approximated by Gaussian distributions. Therefore 200 Gaussian
distributions were generated, one per gene within each archetypal sample, using
the mean and standard deviation of the 12 data points within the given gene and
archetypal sample. Note that only the 12 data points available for each gene were
used to determine the mean and standard deviation because the mean and standard
deviation must be specific to the gene and subtype, whereas all 47 data points per
gene were necessary to form a recognizable distribution. Gaussian distributions were
generated using the “rnorm” function within The R Statistical Package (R) [47].
3.3 Sample Size Justification for Archetypal
Sample Monte Carlo Simulation
Before performing the Monte Carlo simulations an analysis to justify sample size
was performed to ensure sufficient confidence for the analysis when using our target of
100,000 simulated samples. We calculated the 95% confidence interval width around
the percentage of correct classifications using 100,000 simulated samples for each
archetypal sample. For a dichotomous variable (i.e., misclassified or not), a confidence






level (Z0.05 = 1.96), expected proportion of misclassifications (pˆ = 0.02) and the
sample size, or in this case, the number of simulations (n = 100,000). The calculated
confidence interval width is ±0.00087 for each simulation of 100,000 samples, which
is an acceptable value.
3.4 Monte Carlo Simulation Using
Archetypal Samples
Monte Carlo simulations were performed using the mean (µ) value and standard
deviation (σ) for the expression of each gene within the archetypal samples, as
described above. This procedure created a total of 200 independent distributions, i.e.,
50 Gaussian distributions (one for each gene) for each of the four archetypal samples.
For example, the mean expression value (µ) for ACTR3B from the 12 Luminal B
values was 1.94 and the corresponding standard deviation (σ) was 0.085. Therefore
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the ACTR3B expression value for each of the 100,000 simulated Luminal B samples
was randomly selected from a Gaussian distribution centered on a mean (µ) of 1.94
with a standard deviation (σ) of 0.085. Randomly selecting a value from the Gaussian
distribution, as described, does not assume gene expression values are independent of
one another, rather the method assumes that the measurement error for each gene is
independent. Specifically, since each Gaussian distribution is centered on the gene’s
mean expression value for the given sample, any genes within the sample that are
generally upregulated will generally be upregulated in the simulated samples, while
allowing the error to deviate independently. The 100,000 simulated samples for each
archetypal sample were classified using the standard PAM50 process. The effect of
intrinsic gene expression measurement error on the tumor classification was assessed
by determining the percentage of simulated samples that were classified identically
to the original sample. This value provides an estimate of the reproducibility of the
results for archetypal samples.
3.5 Evaluation Using the GEICAM
Independent Test Set
Testing archetypal samples is valuable for determining how the PAM50 assay will
perform under ideal circumstances, but these results may not be informative when the
samples are not as well characterized as the archetypal samples. Thus, the method
described above for the archetypal samples was adapted and applied to the larger
and more diverse set of independent samples from the GEICAM 9906 clinical trial.
A total of 911 breast tumors collected by the GEICAM group for the GEICAM 9906
clinical trial were run and classified by the PAM50. Tumor samples were prepared
following the same methods described above for the archetypal samples and those
with insufficient tumor content to be classified were excluded from further analyses.
3.6 Monte Carlo Simulation using
GEICAM Samples
As depicted in Figure 3.2, the data from the multiple measurements in the archety-
pal samples show that standard deviation depends on the relative average gene
expression value and on the sample subtype. To understand the sample subtype
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dependence one should understand that the expression values of the genes defining
the expression pattern for each of the cancer subtype are quite different, e.g., the
Luminal A subtype expresses all 50 genes at a level that is more easily quantified,
producing a lower standard deviation; however, the HER2-enriched subtype expresses
some genes at lower levels such that they are less easily quantified, producing a
higher standard deviation. Therefore as depicted in Figure 3.2, the relative errors
in the gene expression measurements in a Luminal A sample are smaller than those
in a HER2-enriched sample. Accordingly our methods to produce simulated samples
have to be modified to take into account these dependencies when applied to a set
of nonarchetypal samples. Using locally weighted scatter plot smoothing (loess),
based on the PAM50’s characterized error functions depicted in Figure 3.2, we de-
veloped error distributions that can be used to impose the error on individual test
samples dynamically. The loess model was fit using the R function “loess” (span =
0.75, degree = 1, surface = “direct” and family = “symmetric”) and graphed using
“panel.smoother” from the R lattice graphics package. A 95% confidence interval for
the fitted line was also calculated to test “best-case” (lower limit of the 95% confidence
interval), “worst-case” (upper limit of the 95% confidence interval) and “average-case”
(the fitted line) scenarios for subtype reproducibility. The “worst-case” scenario is
considered as such because it uses the highest estimated standard deviations, or error.
Once the loess models were developed, we used these models to predict the standard
deviation (σ) to generate Gaussian distributions for the Monte Carlo simulation.
Specifically, given the test sample’s original subtype and the expression value for a
given gene, we used the loess model to predict the standard deviation (σ), or error, to
be used in the Gaussian distribution for said gene and sample. The expression value
was used as the mean of the Gaussian distribution. We repeated this process for all
genes within each sample.
The model described above was used to generate random variants of the 847
GEICAM samples remaining after excluding those that could not be classified. The
subtype classification reproducibility for each GEICAM sample was tested by gener-
ating 100,000 simulated samples using Monte Carlo simulations for each of the error
models considered above, i.e., “best-,” “average-” and “worst-case,” for a total of
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300,000 simulated samples per GEICAM sample. Based on the same sample justi-
fication analysis used for the archetypal samples, the calculated confidence interval
width is 0.00087 for each simulation of 100,000 samples, which is an acceptable value.
3.7 Error Effect on PAM50 Results
for GEICAM Samples
After simulating 300,000 samples for each GEICAM sample based on the error
models described above, subtype reproducibility for the individual samples was sum-
marized for each tumor subtype (based on the original sample’s subtype) using two
statistics: (1) the total percentage of simulated samples that did (or did not) change
subtypes with respect to their parent sample and (2) the proportion of simulated
samples, corresponding to a single original sample, that were classified (or misclassi-
fied) identically to the parent sample. These data serve as an estimate of PAM50’s
misclassification rate based on intrinsic error within the assay when samples are not in
proximity to the PAM50 centroids and represents the error effect on PAM50 results.
3.8 Spearman’s Rho (ρ) vs.
Euclidean Distance
Simulations using Spearman’s Rho (ρ) produced results to measure the effect of
technical uncertainty on the clinical PAM50 assay’s results, but does not address
whether the PAM50 would benefit by using a parametric measurement when using
only one gene expression platform, as is the case with the clinical PAM50 assay.
We compared Spearman’s Rho (ρ) to euclidean distance through two methods: (1)
comparing the continuity of PAM50 subtype classifications in hierarchical clusters
when using ρ as a distance metric versus using euclidean distance; and (2) comparing
overall subtype reproducibility (error effect on PAM50 results) between when ρ is
used versus euclidean distance, as described. In this case 1,000 simulated samples
were generated for each parent sample. Statistical significance between using ρ and
euclidean as the distance metric was tested for overall significance (not distinguishing
between subtypes) and for each subtype using the Wilcoxon signed-rank test. The R
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Figure 3.1: Error distributions of the expression values for genes MKI67, MLPH,
and MMP11. These error distributions are representative of those for each of the 50
classifier genes and were used to determine the Gaussian distribution best represented
































































































































































Figure 3.2: Standard deviation as function of expression values and tumor subtype




All simulated samples derived from the archetypal samples were classified as the
same subtype as the parent sample, indicating that the PAM50 subtype classification
for samples with characteristics close to the PAM50 centroids is highly reproducible
and resilient to experimental errors in gene expression measurements. Although this
positive result is encouraging for PAM50 classifications, it is not generalizable beyond
the four archetypal samples.
4.2 GEICAM 9906 Samples
Tables 4.1, 4.2, and 4.3 present the results for the classification of all samples
produced by Monte Carlo simulation using the “best-” (Table 4.1), “average-” (Table
4.2) and “worst-case” (Table 4.3) scenarios for the error models described above.
These scenarios correspond to using the lower values of the 95% confidence interval
for the predicted error-model line, the actual predicted line and the upper values of
the 95% confidence interval, respectively. The upper values of the 95% confidence
interval are representative of the “worst-case” scenario because a greater amount of
error is introduced into the simulation.
Results for the GEICAM sample simulations suggest that all subtype classes are
highly reproducible. When considering the three different error models, the most
reproducible subtype among all GEICAM samples was always the Basal-like for
which 98.47% (average-case) of the simulated samples did not change classification,
followed by Luminal B (96.63%, average-case), Luminal A (95.46%, average-case) and
HER2-enriched (90.07%, average-case). The differences in reproducibility between
“best-” and “worst-case” (“best-case” percentages minus “worst-case” percentages)
in percentage points are 0.89, 1.31, 1.31, and 4.35 for Basal-like, Luminal B, Luminal
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A, and HER2-enriched, respectively. Consequently, the selection of the error model
is not a determining factor in assessing the robustness of the classification due to
experimental errors in gene expression measurement.
Figure 4.1 presents the histogram depicting the percentage of simulated samples,
corresponding to a single parent sample, that change. Based on the “average-case”
simulations and analyzing the classification of the 100,000 simulated samples gener-
ated for each sample we found that 80% (68 of 85) of Basal-like samples never change
subtype during the Monte Carlo simulation, 69% (186 of 270) of Luminal B samples
never change, 59% (178 of 303) of Luminal A samples never change and 22% (42
of 189) of HER2-enriched samples never change subtype. These values correspond
approximately to the first “bucket” in the histogram. While the histograms confirm
the results from Tables 4.1, 4.2, and 4.3 on the general robustness of the PAM50
classification, they also reveal that there are a nonnegligible number of samples
for which a large number of simulated samples change classification. For instance
the most variable sample for Basal-like, Luminal B, Luminal A and HER2-enriched
changed in 42%, 86%, 67% and 75% of the simulated samples, respectively. As
an example, the sample named “GEICAM 09-02639 UU” was originally classified
as HER2-enriched, but 38.7% of its simulated samples were classified as something
else. Specifically, the simulated samples were classified as HER2-enriched 61.3% of
the time, Luminal A 21.4% of the time and Normal-like 17.3% of the time. These
percentages could be translated into probabilities that can be reported to clinicians
using a scorecard like the one depicted in Figure 4.2.
4.3 Distance Metrics
Figure 4.3 presents a hierarchical cluster of all samples from the GEICAM 9906
clinical trial comparing the continuity of PAM50 subtype classifications when using
Spearman’s Rho (ρ) as a distance metric versus using euclidean distance. Subtype
classifications are colored according to Luminal A (dark blue), Luminal B (light blue),
HER2-enriched (pink), Basal-like (red), and Normal-like (green); and are separated
by euclidean (top row) and Spearman’s Rho (denoted “Clinical”). The continuity
of the euclidean classifications is noticeably superior within the HER2-enriched and
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Luminal B groups, and moderately better within the Basal and Luminal A groups.
Table 4.4 presents the results for the classification of all samples produced by
Monte Carlo simulation using the “average-case” scenario for the error models de-
scribed, with the exception of using of using euclidean as the distance metric. Results
suggest that euclidean provides a more reproducible classification for each PAM50
subtype when using data from within one gene expression platform (RT-qPCR in
this case), which may also be generalizable to other cbMVAs. As with Spearman’s
Rho (ρ), Basal-like was most reproducible with 98.81% of the simulated samples
not changing classification, followed by Luminal B (97.76%), Luminal A (97.45%),
and HER2-enriched (93.79%) – though the gap between Luminal A and Luminal B
is markedly smaller. The differences in reproducibility between the “average-case”
for euclidean and Spearman’s Rho (ρ) (euclidean percentages minus Spearman’s Rho
percentages) in percentage points are 0.34, 1.13, 1.99, and 3.72 for Basal-like, Luminal
B, Luminal A, and HER2-enriched, respectively.
Furthermore, Figure 4.4, in contrast to Figure 4.1, presents the histogram depict-
ing the percentage of simulated samples, corresponding to a single parent sample,
that change when using euclidean as the distance metric. There is a markedly strong
left-shift towards zero, including a dramatic decrease in the maximum value within
each subtype. Results from the Wilcoxon signed-rank test demonstrate a statistically
significant increase for the overall change (p < 6.87× 10−8), i.e., treating all subtypes
together. Also, when treating subtypes independently, Luminal A (p < 0.002),
Luminal B (p < 2.90× 10−6), and Basal-like (p < 0.049) were statistically significant,
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Figure 4.1: Distribution of subtype reproducibility for replicas of individual GE-
ICAM samples. Each of the four histograms shows on the y-axis the percentage of













































































































































































































































































































































































































































































































Figure 4.3: Hierarchical clustering of RT-qPCR data for the PAM50 classifier genes
normalized to the 5 control genes using samples from the GEICAM 9906 clinical trial.
Continuity of PAM50 subtype classifications when using Spearman’s Rho (ρ) as a
distance metric versus using euclidean distance. Subtype classifications are colored
according to Luminal A (dark blue), Luminal B (light blue), HER2-enriched (pink),
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Figure 4.4: Distribution of subtype reproducibility for replicas of individual GE-
ICAM samples when using euclidean as the distance metric. Each of the four
histograms shows on the y-axis the percentage of parent samples for which there




MVAs are becoming commonplace, particularly in oncology, to assist treatment
decisions; however, in combination with the advantages of MVAs, there are issues that
must be addressed to ensure MVAs are reliable and personalized. As secrets of the
human genome continue to be unlocked, MVAs are likely to become more common,
still. Thus, measures must be taken to assess the intrinsic technical uncertainty of
MVAs, yet there is currently no standard method for this purpose. The research pre-
sented has made valuable contributions to fill some of the aforementioned knowledge
gaps; specifically, contributions made are as follows:
1. A method to characterize the intrinsic technical uncertainty of MVAs and its
effects on the final result
2. A method that advances MVAs towards personalized healthcare by providing
personalized confidence measurements on the MVA’s result.
3. Explored effectiveness of using a parametric measurement within platform ver-
sus using a nonparametric measurement.
Perhaps the paramount issue to address with MVAs is how to characterize the
effects of intrinsic technical uncertainty on an MVA’s final result; or, in other words,
to have a method capable of grasping how variation (error), no matter the size, affects
the MVA’s final result given the complexity of the MVA. In the PAM50, for example,
the expression of 50 classifier genes are measured in 50 separate RT-qPCR reactions
(in addition to the five housekeeper genes), essentially creating a 50 dimensional
space with each dimension bringing its own associated error, with added potential to
make results unpredictable. The method described in this research can be applied in
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at least two ways, to characterize the reproducibility of PAM50 classifications: (1)
the method can be used to measure the effect of error on the final results, given
a known error; and (2) error limits can be defined, given an acceptable amount of
classification reproducibility. Additionally, this method is believed to be generalizable
to any problem that is based on continuous data values, which provides immediate
relevance to numerous disciplines.
In addition to providing a generalizable method to assess the effects of technical
uncertainty, another consequential issue was to develop a method to provide person-
alized confidence measurements on the assay result. At present, there is a strong
effort by worldwide government agencies, hospitals, physicians, and researchers to
bring personalized medicine to fruition. If medicine is indeed to become personalized,
there must also be a method to describe a result’s confidence for a single patient
sample rather than a summarizing statistic of the overall accuracy of an assay. This
research broached the barrier to provide a personalized confidence measurement and
will promote improved patient care by informing physicians of the MVA’s confidence
in the final result.
Similarly, defining under what circumstances a parametric or nonparametric mea-
surement, and which specific measurement, should be employed is critical to designing
cbMVAs. Which measurement to use will undoubtedly depend on the cbMVA design;
however, based on the research presented, there is evidence that parametric may be
the best choice within a single platform. Although the research presented needs to be
expanded, it laid ground work to better understand the effects of parametric versus
nonparametric statistical measurements within single gene expression platforms.
5.2 Limitations
The methods presented in this research are thorough, necessary, and well-founded;
however, there are inherent limitations that must either be taken into consideration
or may necessitate further research. Known limitations are as follows:
1. The general method to characterize technical uncertainty in MVAs requires
generating a model to generalize variation. Models cannot perfectly represent
the true nature of a system.
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(a) The repeated measures experiment is an estimate of the error
(b) It is assumed that error varies independently (Note: it is not assumed that
genes vary independently)
2. The method does not account for uncertainty beyond what is technical (e.g.,
tumor heterogeneity)
3. The confidence measurement only measures the confidence that a sample is
properly classified according to the defined classes (i.e., assumes the class defi-
nitions accurately represent the biology)
4. Euclidean distance shows greater reproducibility, however, the work presented
does not quantify accuracy
Despite meticulous efforts researchers may make to develop a model, no model
can fully represent the intricate details of a system or process. According to the New
Oxford American Dictionary, a model is “a simplified description. . . of a system or
process, to assist calculations and predictions” [48]. In the case of the model described
in this research, there are two specific limitations: (1) the repeated measures experi-
ment is only an estimate of the error; and (2) error is assumed to vary independently
between genes. Both of the aforementioned limitations have minimal implications
when addressed appropriately. In the first case, performing a sufficient number
of repeated measures will produce an accurate estimate within a small confidence
interval. In the second case, a correlation test can be performed using the repeated
measures data to determine if there is any significant correlation of the error between
genes. If significant correlation is discovered, error could then be varied dependently,
according to the associations discovered.
Perhaps the most apparent limitation of the method presented is that it only
pertains to technical uncertainty and it does not account for outside factors such as,
in the case of the PAM50, tumor heterogeneity, tumor isolation (i.e., directed punch
versus full-face cut), and RNA extraction, among others. Accounting for the factors
specified will require an entirely different study design and cannot be addressed with
the data prepared for this research.
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A perhaps more obscure limitation is that the confidence measurement developed
only measures the confidence that a sample is properly classified according to the
defined classes – meaning the measure assumes class definitions accurately represent
the biology. While knowing the confidence of the classification according to the
defined classes is important, it should be clear to anyone interpreting the results
that the defined classes have limitations of their own. Specifically, anytime classes are
imposed on continuous data values, there will be boundaries that engenders ambiguity,
by definition.
A final limitation worth mentioning is that the research contrasting euclidean
and Spearman’s Rho (ρ) as distance metrics does not quantify accuracy, though
euclidean distance is demonstrated to have superior reproducibility. Reproducibility
is essential to any MVA, at which euclidean distance is clearly superior to ρ, but
without a comprehensive comparison of accuracy, judgement cannot be fully exe-
cuted. On the other hand, there is preliminary evidence that euclidean distance may
also have superior accuracy because of the superior classification continuity within
the hierarchical cluster – though that is assuming class definitions and hierarchical
clustering accurately represent the biology. Further research is necessary to determine
whether euclidean, and parametric measurements alike, are more accurate than ρ and
other nonparametric measurements within a single gene expression platform.
5.3 Opportunities for Future Work
Scientific research is a complex, never-ending process that often rouses more
questions to be explored than were answered to begin with. The complexity of
individual disciplines such as biology, medicine, and informatics as separate entities
(or silos) is enough to occupy a researcher for the duration of his or her career. Yet,
trying to utilize biology, medicine, and informatics together, such as is the case with
biomedical informatics, seems to increase the complexity in a nonlinear fashion. Given
the methods presented in this research traverse all of the specified disciplines, there are
diverse opportunities for future work to clarify and ameliorate the characterization of
intrinsic technical uncertainty in MVAs. Two general areas, with broad implications,
that need further work are to : (1) explore nontechnical uncertainty; and (2) explore
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the implications of parametric versus nonparametric measures.
Exploring nontechnical uncertainty alone requires extensive knowledge and ex-
perimentation within biology, medicine, and informatics. Within biology there are
questions regarding genetics, heritability, genomics, and proteomics. For example, it
is possible the disease was genetic (directly predisposed), or on the other hand there
may have been a genetic weakness that made the patient more susceptible to the
disease (indirectly predisposed); there are important treatment implications based on
the genetics. Likewise, heritability, which accounts for relative contributions of genetic
and nongenetic (e.g., environmental) differences, has important implications. Further-
more, deeper knowledge of genomics and proteomics will provide direct insight for
drug development. Combining the biology with medicinal expertise (e.g., pathology,
internal medicine, etc.) and informatics (computer science, statistics, data storage,
data mining, etc.) presents numerous paths to not only improve treatment, but
the MVAs used to help determine the ideal treatment. Areas of immediate interest,
specific to the PAM50, are understanding the effects of tumor heterogeneity, tumor
isolation (i.e., directed punch versus full-face cut), and RNA extraction methods.
There are many opportunities to improve this work.
Exploring the implications of parametric versus nonparametric measures, though
perhaps less complex, is a formidable challenge. Not only exploring parametric
versus nonparametric measures, but there are numerous measures within each class.
Additionally, the results are likely to change based on the MVA design, whether
there are one or multiple platforms employed, and the underlying natural value
distributions. It may, in fact, be that there are few generalizations to be made,
and that the various options available will need to be tested individually for each
MVA.
5.4 Relevance to Biomedical Informatics
Biomedical informatics is a multidisciplinary field and, as defined by Shortliffe
and Blois, is “the scientific field that deals with biomedical information, data, and
knowledge – their storage, retrieval, and optimal use for problem solving and decision
making” [49]. Essentially, biomedical informatics will play a critical role in improving
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patient care by improving physician access to, and understanding of biomedical
information. Among the many topics within the realm of biomedical informatics,
improving MVAs is a critical piece to realize improved patient care, since physicians
will be able to make more informed decisions. This research has improved MVAs in
the following fashions: (1) developed a generalizable method to characterize intrinsic
technical uncertainty in MVAs; (2) developed a method to provide personalized confi-
dence measurements for individual patient samples; and (3) laid ground work to better
understand the effects of parametric versus nonparametric statistical measurements
within single gene expression platforms.
A generalizable method to characterize intrinsic technical uncertainty in MVAs
will become increasingly important as scientific and medical breakthroughs allow
for more complex MVAs to provide personalized treatment guidance. Moreover,
MVAs will likely become more complex over time and there must be methods to
characterize the intrinsic technical uncertainty within the MVA to ensure the MVAs
are reproducible and accurate. The method described was developed for and tested
on the PAM50, but the principles employed are generalizable to any assay based
on continuous data values; and training in biomedical informatics facilitated the
method’s development.
At present, there is a strong effort by worldwide government agencies, hospitals,
physicians, and researchers to bring personalized medicine to fruition. If medicine is
indeed to become personalized, there must also be a method to describe a result’s
confidence for a single patient sample rather than a summarizing statistic of the
overall accuracy of an assay. This research broached the barrier to provide a person-
alized confidence measurement and will promote improved patient care by informing
physicians of the MVA’s confidence in the final result.
Although there is much work to be done to understand when parametric and
nonparametric statistical measurements should be employed, not to mention which of
the many available measurements within either class, there is evidence that parametric
may be the best choice within a single platform. A deeper understanding of the
intricacies of statistical measurements for use in MVAs will allow for more reliable
and accurate MVAs – an important task within biomedical informatics.
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Each contribution from this research was facilitated by training in biomedical
informatics. Many researchers have spoken of, and endeavored to overcome, the
silo-like nature of historical disciplines [50–53] such as biology, medicine, and statistics
– and the biomedical informatics discipline is a direct result of their efforts. By seeking
to bring together the knowledge from several “silos,” this research achieved tasks that
otherwise may have been overlooked.
CHAPTER 6
CONCLUSION
A method was developed based on Monte Carlo simulations and limited exper-
imental measurements to estimate the effect of the intrinsic experimental errors
in the measured factors contributing to MVAs. While the specifics of the error
distribution functions given are not universal functions, and recalculation for each
lab or experimental setting must be considered, the proposed method is generalizable
and adaptable to any MVA.
Furthermore, the method presented advances MVAs towards personalized health-
care by providing personalized confidence measurements on the assay result. Provid-
ing personalized confidence measurements on the assay result will allow physicians
to make better treatment decisions, although the confidence measure assumes that
classes accurately represent the disease’s biology.
While the effectiveness of using a parametric measurement within platform versus
using a nonparametric measurement is inconclusive, the data presented suggest that
parametric measurements may be better suited for use within a single platform.
Further understanding of the effects of parametric versus nonparametric under various
circumstances will be invaluable for the design of future MVAs.
Finally, using the proposed method based on Monte Carlo simulations and the
error model described here, we have presented data that suggests PAM50’s subtype
classifications are highly reproducible on a large, independent sample set from the
GEICAM 9906 clinical trial. We also show that there are a nonnegligible number of
samples for which a significant number of the Monte Carlo simulated samples classify
differently than the parent sample, indicating that the classification of the original
sample may not be reliable – thus highlighting the need for the new score card that
can inform clinicians on the probability that a particular sample could be classified
as a different tumor subtype.
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